Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYR.F
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0140 USD | 0.00% |
|
0.00% | -89.24% |
| Market Cap | 20.37M 14.57M 12.6M 11.59M 10.87M 1.39B 20.69M 138M 53.41M 675M 54.77M 53.6M 2.33B | P/E Ratio 2024 |
-5.24x | P/E Ratio 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 20.14M 14.4M 12.45M 11.46M 10.75M 1.38B 20.46M 136M 52.8M 668M 54.15M 52.99M 2.31B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
91.6% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 month | -81.33% | ||
| 3 months | -88.14% | ||
| 6 months | -86.00% | ||
| Current year | -89.24% |
| 1 month | 0.01 | 0.08 | |
| Current year | 0.01 | 0.13 | |
| 1 year | 0 | 0.24 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 2019-06-30 |
| Director of Finance/CFO | - | 2022-08-16 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 2024-09-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 2017-12-05 |
Brad Willis
BRD | Director/Board Member | - | 2019-06-30 |
Eric Pommer
CHM | Chairman | - | 2025-04-29 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | - | - | 16.25M | ||
| +2.16% | +7.62% | +43.83% | +160.28% | 1,013B | ||
| -0.07% | +6.76% | +52.34% | +48.95% | 574B | ||
| -0.08% | +3.52% | +18.61% | +62.66% | 397B | ||
| +0.77% | +4.97% | +21.24% | +15.95% | 324B | ||
| +0.85% | +2.79% | +24.89% | +15.93% | 280B | ||
| +2.10% | +7.06% | +24.57% | +34.79% | 273B | ||
| +4.84% | +4.68% | +20.66% | +61.85% | 182B | ||
| -0.19% | +3.96% | -45.64% | -48.23% | 194B | ||
| +3.61% | -2.42% | +14.33% | +61.12% | 151B | ||
| Average | +1.56% | +2.65% | +19.42% | +45.92% | 376.52B | |
| Weighted average by Cap. | +1.61% | +3.99% | +29.36% | +72.50% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34 |
| Net income | -1.71M -1.22M -1.06M -971K -911K -117M -1.73M -11.53M -4.48M -56.59M -4.59M -4.49M -196M | -3.53M -2.53M -2.18M -2.01M -1.88M -241M -3.59M -23.85M -9.26M -117M -9.5M -9.29M -405M |
| Net Debt | -113K -80.55K -69.64K -64.09K -60.09K -7.7M -114K -760K -295K -3.73M -303K -296K -12.9M | -231K -165K -143K -131K -123K -15.76M -234K -1.56M -604K -7.64M -620K -607K -26.41M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYR.F Stock
Select your edition
All financial news and data tailored to specific country editions
















